Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. - Wikidata - wikimedia - TriplyDB

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

http://www.wikidata.org/entity/Q37688257

about

Role of isavuconazole in the treatment of invasive fungal infections Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy Therapeutic Drug Monitoring of Posaconazole: an Update Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections Structural Insights into Binding of the Antifungal Drug Fluconazole to Saccharomyces cerevisiae Lanosterol 14α-Demethylase.Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.Structure-Functional Characterization of Cytochrome P450 Sterol 14α-Demethylase (CYP51B) from Aspergillus fumigatus and Molecular Basis for the Development of Antifungal Drugs.A case report of intravenous posaconazole in hepatic and renal impairment patient with invasive Aspergillus terreus infection: safety and role of therapeutic drug monitoring Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins.Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.Detection of a Serum Siderophore by LC-MS/MS as a Potential Biomarker of Invasive Aspergillosis.Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.Comparison of clinical pharmacology of voriconazole and posaconazole.Burden and distinctive character of allergic bronchopulmonary aspergillosis in India.Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia.Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2014.Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis.Azole antifungals: 35 years of invasive fungal infection management.Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review.Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.Gastroesophageal Reflux Disease and Pulmonary Diseases Associated with Aspergillosis: Is There a Connection?Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.Infection in cystic fibrosis: impact of the environment and climate.Antifungal prophylaxis in newly diagnosed AML patients-Adherence to guidelines and feasibility in a real life setting.New facets of antifungal therapy.Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14α-Demethylase Provides Insights into Its Broad-Spectrum Antifungal Activity.Pharmacokinetics of posaconazole in koalas (Phascolarctos cinereus) after intravenous and oral administration.Pharmacokinetic considerations in treating invasive pediatric fungal infections.

P2860

Q26740837-5C6174A2-8CB0-416C-A7A0-8BCFE95F0242 Q26745677-D02B8A7B-0ABF-4D04-B0C3-0434A65B0E2A Q26746016-436E3AB8-30C4-4BA2-8DAF-4C154448DA9E Q26771180-9805739D-922E-46D5-BDD0-A74DDF7A4F5A Q27324352-83C64637-C811-4336-BA36-5921C07990E8 Q33880412-B6836D2B-29A6-42C1-A53A-49D07420623B Q34532546-58652776-79E4-493A-B65D-7404875847B4 Q34596750-411B191F-523A-4E9D-BBA8-E009C45E521F Q34596950-C2D4AFD8-57CE-4FAC-B307-A2BE2FC81190 Q35169112-A16604FE-37BA-4506-8DAE-4742EEA50298 Q35385786-6E0311F0-8477-468D-8ABC-3FAB10061C50 Q35672258-108FD1A6-E077-4833-8958-7478062ABD84 Q35859959-0E1D485A-7B57-434D-9846-82BB2A292772 Q35954530-EA787DA7-1425-4900-9A39-5F934872E4EF Q36093075-33E81F0C-A2EE-4565-86FC-59876D4A0063 Q36265747-DD72E559-8C1C-4898-9E42-EB810E5459C5 Q36439011-A69B46F9-32F4-4CE0-95A2-273ADCA0FD30 Q36469807-A9D3B02A-0858-403B-8D29-A84F421E1C7C Q36684576-6D299338-8F6A-474D-AE7E-7889523AFDA9 Q36730105-0B77A9B4-C346-4FCE-A6E2-8E505B554552 Q37203849-FB086E92-5253-495D-9852-F7DE6786A751 Q37727651-69CDF2BB-A97C-4FFD-9A17-6AD0A60C9852 Q38221676-25CCE27E-0369-4C48-B8E8-A6F3ED4BC320 Q38264086-489333B4-C14C-4CE9-A1AE-63A86673AB54 Q38284447-4848EA38-8077-4363-B187-E0DC12361BD3 Q38284463-FEF4C67C-11CF-49B5-90EF-3C5D79F15DC1 Q38284468-D9B7FB94-CDAC-4ACC-87F5-DCB0B3BD3325 Q38296370-DD87CA3E-0BEB-4493-BB49-0ABC3F19AF54 Q38406393-84AE8F26-6DEE-42DC-96C1-2F962ED8D7CF Q38526795-E7916879-0E27-4CB1-B4A3-FC4E24F46975 Q38605129-0FBEA8D3-5DF1-4302-BAE4-D323EC002B6B Q38681575-2A9A3E87-E4C2-478D-870B-A18891950E12 Q38738090-B05EF8CC-55D5-4CB1-A402-66F2F2F341E4 Q38758268-C663B885-09D3-41C0-94D7-62FA2BC88CF3 Q38763542-C76629AD-0974-4420-98D1-2D0BEA59D97F Q38786258-872266D3-F382-4B46-A3E6-204DD8375E54 Q38797864-41BC0B86-802E-48D7-8732-EC4B4D6DEAC4 Q38810307-CB59EBE4-B348-41F2-9CE1-D27CCB445910 Q38813173-1309FFC5-BA68-4882-9B00-49E84944BA51 Q38816614-667DA7FC-48F4-4D5B-A67C-8F0EF2A7827A

P2860

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

http://www.wikidata.org/entity/Q37688257

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Therapeutic drug monitoring (T ...... Society for Medical Mycology.

@en

Therapeutic drug monitoring

@nl

type

label

Therapeutic drug monitoring (T ...... Society for Medical Mycology.

@en

Therapeutic drug monitoring

@nl

prefLabel

Therapeutic drug monitoring (T ...... Society for Medical Mycology.

@en

Therapeutic drug monitoring

@nl

P1433

Q37688257-B880E047-E234-474E-80F4-2572925501F6

P1476

Q37688257-2DBB4C12-A9F3-4A59-B769-967C83806F2F

P2093

Q37688257-2E9BC159-0B3A-4310-A03E-030D5B6DBA76

Q37688257-B940F972-151C-41E7-A4AC-413E46AB7F50

Q37688257-CEAF4159-FA22-40B4-A52C-64A07253DB05

Q37688257-D1B5A62A-67CE-444E-9DF4-38FD65F32C8F

P2860

Q37688257-046030FF-EA58-4F02-BC27-506ADA0A66CA

Q37688257-04CA3586-48C3-4838-A7DE-6B61DC5B76BA

Q37688257-056B0F51-2552-4A8E-92C8-C2B22C88C435

Q37688257-09207A52-ACC7-4913-9C7D-3217D01A612C

Q37688257-0B58AD2E-96B6-40D3-8507-0EFE900FC766

Q37688257-0C614A7C-227A-456E-9F06-C5074ED32FB7

Q37688257-0C68A341-A3ED-4CA2-A010-4C6BD80A3235

Q37688257-0E2A7CB9-8AC2-4AE9-AE69-D11045821C9A

Q37688257-0FEFBDFB-5D49-4E02-899F-8D1C02F0192B

Q37688257-1133D292-B57A-4ED1-80C7-35FF5D109E78

P304

Q37688257-F33B9D9C-7000-4E27-84B1-A5CCE52F0938

P31

Q37688257-D98B222B-63C0-4AB1-B998-2186A33620D7

P356

Q37688257-1CC4689C-0E1B-4D2B-87BA-1E19E1EA105E

P407

Q37688257-5C9DCA8C-AF47-4D97-844D-B9AB4E869642

P433

Q37688257-AA78DD49-0835-4F0C-B691-97FAC435D9BA

P478

Q37688257-AE55F556-7209-4792-BD90-33588CD1704D

P50

Q37688257-71F25BCF-F397-4AA8-8DCC-C66AE7F7FDFE

Q37688257-B7081EEA-FA1A-4003-AA94-16B33495316B

P577

Q37688257-CEDD05B3-03BC-4AC1-BBEC-8E8E39EDCBB4

P698

Q37688257-540745AC-84AB-4CE2-8E40-52E9DCF10247

P932

Q37688257-8DCC5ED0-D0C9-4199-86B6-6E31DCC2B5E6

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Therapeutic drug monitoring (T ...... Society for Medical Mycology.

@en

P2093

Elizabeth M Johnson

http://www.w3.org/2001/XMLSchema#string

H Ruth Ashbee

http://www.w3.org/2001/XMLSchema#string

Rebecca Gorton

http://www.w3.org/2001/XMLSchema#string

Rosemary A Barnes

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole therapeutic drug monitoring.

Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis

Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis.

Voriconazole pharmacokinetics and pharmacodynamics in children.

Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi

P304

1162-1176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKT508

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Malcolm Richardson

P577

2013-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24379304

http://www.w3.org/2001/XMLSchema#string

P932

3977608

http://www.w3.org/2001/XMLSchema#string